Breakthrough ADC Therapy for Treatment of Bladder Cancer

1
Breakthrough ADC Therapy for Treatment of
Bladder Cancer
https//www.creative-biolabs.com/adc/
2
Introduction
Recently, Seattle Genetics and Astellas announced
their latest data on Phase 1 clinical trials of
enfortumab vedotin at the ASCO Annual Meeting.
Research shows that this innovative treatment has
shown promising results in the treatment of
metastatic urothelial carcinoma. According to
the American Cancer Society, urothelial carcinoma
is the most common type of bladder cancer,
accounting for 90 of the total number of cases.
It is estimated that 81,000 patients will have
newly diagnosed bladder cancer this year. Once
this cancer metastasizes, the patient's prognosis
is quite poor. The data shows that the 5-year
survival rate of patients is only 4.8.
3
1
The enfortumab vedotin brought by Seattle
Genetics and Astellas is expected to bring a good
news to bladder cancer patients. This is an
antibody drug conjugate (ADC) under development.
It consists of two parts one is a monoclonal
antibody targeting Nectin-4, a common molecule on
the surface of solid tumors, and the other is a
microtubule destroyer MMAE. According to design,
this new drug can identify cancer cells with
Nectin-4 and kill it precisely. Not long ago, the
United States FDA granted this new drug
breakthrough therapy treatment to treat locally
advanced or metastatic urothelial carcinoma.
Enfortumab Vedotin
4
For urothelial carcinoma, enfortumab vedotin
showed promising results in a clinical trial
called EV-101. The trial recruited a total of 112
patients who had metastatic urothelial carcinoma
and had been treated with chemotherapy. Studies
have shown that the overall response rate of
enfortumab vedotin is 41, with 4 of them
achieving complete remission (3.6). It is worth
noting that of the 112 patients, 89 had
previously received treatment for an immune
checkpoint inhibitor. In this patient population,
the overall response rate for this innovative ADC
is 40.
5
Dr. Robert Lechleider Said
The senior vice president of clinical development
at Seattle Genetics.
"Many patients with locally advanced or
metastatic urothelial carcinoma who have received
treatment with immunologic checkpoint inhibitors
tend to have a poor prognosis and have limited
use of therapies," said Dr. Jonathan E.
Rosenberg, reporting data for the study. "From
the current objective response rate and
preliminary survival data, enfortumab vedotin has
potential for the treatment of locally advanced
or metastatic urothelial carcinoma."
6
We expect the successful development of this
therapy, which will bring breakthrough new drugs
to patients with metastatic urothelial carcinoma
who lack effective therapy.
7
Established in 2004, Creative Biolabs is highly
specialized in advanced antibody biochemistry and
engineering, including ADC customs products. With
more than a decade of exploration and expansion,
our current research and service capacity covers
the entire new drug discovery and antibody
conjugation service, which ranges from early
discovery, pre-clinical evaluations, cGMP
manufacturing, dar conjugation to clinical
trials. As an international cooperation, Creative
Biolabs has established multiple offices all
around the globe with more than 200 well-trained
full-time scientists and technicians, who work
closely with our customers and research partners
to develop new medicines for a better, healthier
world.
Creative Biolabs
8
Contact Us
45-1 Ramsey Road, Shirley, NY 11967, USA
Email marketing_at_creative-biolabs.com
9
Thank You
https//www.creative-biolabs.com/adc/